title: Novel Approaches to Thyroid Cancer Treatment and Response Assessment.
abstract: The incidence of thyroid cancer has been increasing. After total thyroidectomy of well-differentiated thyroid tumors with intermediate- or high-risk features on pathology, radioiodine remains one of the mainstays of therapy for both thyroid remnant ablation as well as for treatment of metastatic disease. SPECT/CT, a relatively new modality, has been shown to play a pivotal role predominantly in the post-therapy setting by changing the risk stratification of patients with thyroid cancer. In the case of radioiodine treatment failure, FDG-PET/CT may provide prognostic information based on extent and intensity of metabolically active metastatic sites as well as serve as an important imaging test for response assessment in patients treated with chemotherapy, targeted therapies, or radiotherapy, thereby affecting patient management in multiple ways. The role of newer redifferentiation drugs has been evaluated with the use of I-124 PET/CT.
authors.affiliation: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: grewalr@mskcc.org.
authors.forename: Ravinder K
authors.initials: RK
authors.lastname: Grewal
authors.affiliation: Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Alan
authors.initials: A
authors.lastname: Ho
authors.affiliation: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Heiko
authors.initials: H
authors.lastname: Schöder
mesh_terms: D000818:Animals; D003952:Diagnostic Imaging; D006801:Humans; D058990:Molecular Targeted Therapy; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome